My name is Shuling Guo. I earned my Ph.D. in Molecular Cancer Biology from Duke University and completed my postdoctoral training at HHMI/UCLA. Since joining Ionis Pharmaceuticals in 2008, I have steadily taken on increasing responsibilities and currently hold the position of Vice President of Drug Discovery.

In my role, I manage the drug discovery activities within the CardioRenal, Metabolic, and Pulmonary franchises. My responsibilities span the entire drug discovery process, from target identification, target validation, to the selection of human development candidates. Additionally, I am closely involved in the clinical development of RNA therapeutics. Under my supervision, many compounds have been approved (e.g. Tegsedi®), in registration (e.g. WainuaTM), or at various stages of development (e.g. Sapablursen in phase 2 development) in the past 15 years. Recently, I have extended my expertise beyond gene silencing, now delving into the realm of gene editing through the innovative use of CRISPR technology.

Throughout my tenure, I have also overseen exploratory research initiatives, investigating areas such as noncoding RNA, autophagy/mitophagy, and nonsense-mediated mRNA decay. To date, I have published over 70 articles, a majority of which are related to the applications and mechanisms of antisense technology in various therapeutic areas.

AFFILIATIONS:

• Member, Oligonucleotide Therapeutics Society (OTS)
• Member, American Society of Nephrology (ASN)
• Member, American Thoracic Society (ATS)
• Member, International BioIron Society (IBIS)
• Member, TIDES advisory committee